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ABSTRACT: Pancreatic cancer has a dismal 5 year survival rate of 5.5% that has not been improved over the past 25 years
despite an enormous amount of effort. Thus, there is an urgent need to identify truly novel yet druggable protein targets for drug
discovery. The human protein DnaJ homologue subfamily A member 1 (DNAJA1) was previously shown to be downregulated 5-
fold in pancreatic cancer cells and has been targeted as a biomarker for pancreatic cancer, but little is known about the specific
biological function for DNAJA1 or the other members of the DnaJ family encoded in the human genome. Our results suggest the
overexpression of DNAJA1 suppresses the stress response capabilities of the oncogenic transcription factor, c-Jun, and results in
the diminution of cell survival. DNAJA1 likely activates a DnaK protein by forming a complex that suppresses the JNK pathway,
the hyperphosphorylation of c-Jun, and the anti-apoptosis state found in pancreatic cancer cells. A high-quality nuclear magnetic
resonance solution structure of the J-domain of DNAJA1 combined with a bioinformatics analysis and a ligand affinity screen
identifies a potential DnaK binding site, which is also predicted to overlap with an inhibitory binding site, suggesting DNAJA1
activity is highly regulated.
Despite the decline of cancer-related mortality in the pastdecade, effective approaches to early diagnosis and
treatment of pancreatic cancer remain elusive. Although it
accounts for only 3% (43000 new cases every year) of all
cancers, pancreatic cancer is the fourth leading cause of cancer
death in the United States (37000 deaths annually) and has the
highest mortality rate of any cancer.1,2 Those with an operable
early stage of the disease have a 5 year survival rate of ∼20%.2,3
Unfortunately, 80% of all pancreatic cancer diagnoses indicate
an advanced stage of the disease that is beyond the point of
surgery.1,3,4 Inoperable forms of pancreatic cancer have a 5 year
survival rate of only 3%. The difficulty in detecting or
diagnosing pancreatic cancer has several causes: the early
stages of pancreatic cancer do not typically exhibit symptoms;
the symptoms that do occur are often similar to those of other
illnesses; and the location of the pancreas behind other organs
can hinder detection.1
Most patients with advanced pancreatic cancer are treated
with chemotherapy based on gemcitabine, which is a cytotoxic
nucleoside drug that primarily inhibits DNA synthesis.5
However, this treatment is only mildly effective for patients
with an advanced stage of pancreatic cancer and provides an
only 5.91 month increase in the median survival rate.6 Also,
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gemcitabine-resistant forms of pancreatic cancer and acquired
resistance during treatment are common problems.7 Corre-
spondingly, there have been numerous attempts to combine
gemcitabine with other cytotoxic agents, such as 5-fluorouracil
or capecitabine. However, these approaches have been mostly
unsuccessful.8 It is apparent that a cytotoxic approach to
treating pancreatic cancer is not an effective therapy. Therefore,
identifying novel, but druggable, protein targets for the
treatment of pancreatic cancer and improving the quality of
life for patients are essential needs.
The DnaJ proteins, also known as heat shock protein 40
(Hsp40 or Hsc40), are proteins originally identified in
Escherichia coli that act as cochaperones to the molecular
chaperone DnaK (Hsp70), which is responsible for several
cellular processes such as rescuing misfolded proteins, folding
polypeptide chains, transport of polypeptides through mem-
branes, assembly and disassembly of protein complexes, and
control of regulatory proteins.9−11 DnaJ primarily facilitates the
hydrolysis of ATP from DnaK that is necessary for the
chaperone activity of DnaK.11−13 In general, J-domain proteins
modulate protein assembly, disassembly, and translocation.14
Human protein DnaJ subfamily A member 1 (DNAJA1) has
been shown to associate on its own with unfolded polypeptide
chains and prevent their aggregation,15 to regulate androgen
receptor signaling and spermatogenosis in mice,16 and to
contribute to the resistance of glioblastomas to radiotherapy.17
DNAJA1 has also been targeted as a biomarker for pancreatic
cancer to evaluate the effects of farnesyl protein transferase
inhibitors18,19 and has been shown to be downregulated 5-fold
in a genomics analysis of pancreatic cancer cells relative to
normal healthy cells and cells undergoing pancreatitis.20
Additionally, DNAJA1 appears to be involved in importing
proteins into the mitochondria.21,22 Of note, the mitochondrial
pathway to apoptosis protects against cancer and requires
importing apoptotic factors into the mitochondrial mem-
brane.23−26 Additionally, DNAJA1 is an interesting target based
on its association with DnaK, which is expressed abundantly in
various tumors and can potentially promote tumorigenesis by
inhibiting cell death.27−32 However, there have been no studies
of whether the conserved J-domain of DnaJ alone has any role
in cancer biology independent of DnaK.10
Thus, DNAJA1 was selected for further analysis as a
potentially interesting therapeutic target for the treatment of
pancreatic cancer. The potential importance of DNAJA1 to
pancreatic cancer was demonstrated by stress response cell-
based assays using cell lines overexpressing DNAJA1. DNAJA1
was shown to regulate the hyperphosphorylation of c-Jun and
cell survivability under stress. The resulting nuclear magnetic
resonance (NMR) structure of the J-domain of DNAJA1
(DNAJA1-JD) combined with a detailed bioinformatics analysis
predicted the location of overlapping activating and inhibitory
protein binding sites. A subsequent NMR−ligand affinity
screen provided further experimental support for the existence
of the predicted inhibitory protein binding sites and also
demonstrated that the J-domain of DNAJA1 is a potential
druggable target. In total, our results suggest DNAJA1 activity is
highly regulated and that DNAJA1 is involved in a stress
response signaling pathway that suppresses the anti-apoptosis
state found in pancreatic cancer cells.
■ EXPERIMENTAL PROCEDURES
Effect of DNAJA1 Overexpression on Cellular Stress
Modulation in Pancreatic Cancer Cells. MiaPaCa2 cells
were obtained from the American Type Culture Collection
(Rockville, MD). Cells were cultured as previously described.33
Briefly, MiaPaCa2 cells were maintained in Dulbecco’s
modified Eagle’s medium (Life Technologies, Carlsbad, CA)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS), nonessential amino acids, sodium pyruvate, and
penicillin/streptomycin in a 37 °C incubator with 5% CO2.
To stably express the full-length His-tagged DNAJA1 construct,
retroviral transductions were conducted essentially as described
previously.34 The DNAJA1 construct was purchased from the
Arizona State University Biodesign Institute (http://dnasu.org/
DNASU/Home.jsp).
Cell lysates were prepared by scraping cells (80−90%
confluent) into lysis buffer [50 mM Tris-HCl (pH 7.5), 0.15
M NaCl, 1% (v/v) Triton X-100, 1% (w/v) sodium
deoxycholate, 0.1% (w/v) SDS, 5 mM EDTA, and 1 mM
phenylmethanesulfonyl fluoride]. Lysates were incubated, on
ice, for 30 min and centrifuged at 4 °C for 15 min at 13000 rpm
to remove cell debris. Supernatants were transferred to fresh
tubes, and the protein content was determined using the
Bradford protein assay reagent (Bio-Rad, Hercules, CA) with
various concentrations of bovine serum albumin as standards.
Cell lysates were stored at −20 or −80 °C. Cell lysate proteins
were resolved on 10 or 12% Tris-glycine denaturing
polyacrylamide gels in 1× sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS−PAGE) buffer (1 g/L SDS, 3 g/
L Tris base, and 14.4 g/L glycine). Western blotting was
performed as previously described.35,36 The membranes were
probed with primary antibodies against phosphoS63-c-Jun
[2361 (Cell Signaling Technology, Danvers, MA)], total c-Jun
[9165 (Cell Signaling Technology)], the His tag [2365 (Cell
Signaling Technology)], and tubulin [E7 (Developmental
Studies Hybridoma Bank, Iowa City, IA)]. The primary
antibody treatments were performed overnight at 4 °C at
1:1000 dilutions.
Cell survival was evaluated by the MTT [3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide] assay as described
elsewhere.37 Cells were plated in triplicate in 96-well plates at a
density of 5000 cells/well and incubated at 37 °C. Twelve
hours later, cells were treated with anisomysin (10 μg/mL) or
solvent control [dimethyl sulfoxide (DMSO)] and incubated
for 24 h. At the end point, the culture medium was removed
and 20 μL of the MTT solution [5 mg/mL (Sigma-Aldrich, St.
Louis, MO)] was added per well, followed by a 2 h incubation.
MTT was removed, and 200 μL of DMSO was added to each
well to dissolve formazan. The formazan optical density was
determined by utilizing a microplate reader (FLUOstar Omega,
BMG LABTECH, Cary, NC) at a wavelength of 540 nm.
Solution Structure of the DNAJA1 J-Domain. The full-
length human DNAJA1 protein (397 amino acids) has been
targeted by the Northeast Structural Genomics Consortium
[NESG (http://www.nesg.org)] for structural elucidation as
target HR3099 (UniProt entry P31689) (Figure 1).
Samples of approximately 100% 15N-enriched, 5% 13C-
enriched, and uniformly 13C- and 15N-enriched DNAJA1-JD
[77 amino acids with 10 non-native residues, MGHHHHHH-
SH, at the N-terminus for purification (NESG entry
HR3099K)] were produced using the standard protocols of
the NESG.38,39 The protein construct containing the sequence
for DNAJA1-JD was transformed into BL21(DE3)+Magic cells.
The soluble fraction of the lysed cells was collected and purified
with a Ni+ affinity column (HisTrap HP 5 mL column, GE
Healthcare, Pittsburgh, PA) and a gel filtration column
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(HiLoad 26/60 Superdex 75 prep grade, GE Healthcare). The
sample identity and isotopic enrichment were validated by
matrix-assisted laser desorption ionization time-of-flight mass
spectrometry, and the homogeneity (>97%) was assessed by
SDS−PAGE. The NMR protein sample was stored in a sealed
Shigemi tube with 20 mM 2-(4-morpholino)ethanesulfonic acid
[MES (Sigma-Aldrich)] buffer [pH 6.5 (uncorrected)] with
10% D2O (Sigma-Aldrich), 0.02% NaN3 (Sigma-Aldrich), 10
mM dithiothreitol [DTT (Sigma-Aldrich)], 5 mM CaCl2
(Sigma-Aldrich), 100 mM NaCl (Sigma-Aldrich), and 50 μM
4,4-dimethyl-4-silapentane-1-sulfonic acid [DSS (Sigma-Al-
drich)].
NMR experiments used for the protein backbone and side-
chain assignments of DNAJA1-JD were collected at 298 K on a
600 MHz Bruker Avance spectrometer equipped with a 5 mm
TXI probe. The backbone and side-chain assignments were
completed using the standard triple-resonance approach40−42 of
the following NMR experiments: two-dimensional (2D)
1H−15N HSQC, 2D 1H−13C HSQC, and three-dimensional
(3D) HNCO; HN(CA)CO; HNCA; HN(CO)CA; CBCA-
(CO)NH; CBCANH; HNHA; HBHA(CO)NH; CC(CO)-
NH; HCC(CO)NH; HCCH-COSY; and HCCH-TOCSY.
15N-edited NOESY-HSQC and 13C-edited NOESY-HSQC
experiments (mixing times of 120 ms) were conducted on a
500 MHz Bruker Avance DRX spectrometer equipped with a
triple-resonance, Z-axis gradient cryoprobe to identify nuclear
Overhauser effects (NOEs). Amide hydrogen exchange rates
were also evaluated on the 500 MHz Bruker Avance DRX
spectrometer using the (CLEANEX-PM)-FHSQC experiment.
The NMR experimental data were processed using
NMRPipe43 and evaluated in CCPNMR Analysis (http://
www.ccpn.ac.uk).44 An initial model of DNAJA1-JD was
generated from the protein backbone resonances using CS-
ROSETTA on the WeNMR GRID-enabled web portal (http://
www.enmr.eu/webportal).45−47
The initial model of DNAJA1-JD was refined with XPLOR-
NIH version 2.3148 using the following experimental restraints:
1070 NOE distance restraints, 50 H-bond distance and angle
restraints, 38 3JNHα coupling constant restraints, 127
13Cα/13Cβ
chemical shift restraints, and 116 dihedral angle restraints
predicted from TALOS+.49 All peptide bonds were constrained
to be planar and trans. A total of 400 structures were calculated,
with the 20 lowest-energy structures being subjected to explicit
water refinement based on the RECOORD protocols.50 An
average DNAJA1-JD structure was calculated on the basis of the
average atom coordinates of the 20 water-refined structures and
subsequently minimized using the same explicit water refine-
ment described above.
The resulting structures were evaluated using the RPF
webserver (http://nmr.cabm.rutgers.edu/rpf/)51 and PSVS
software suite (http://psvs-1_5-dev.nesg.org/),52 which in-
cludes Verify3D,53 ProsaII,54 PROCHECK,55 and Molpro-
bity.56 The three-dimensional structures of the proteins are
represented here using the UCSF Chimera package from the
Resource for Biocomputing, Visualization, and Informatics at
the University of California, San Francisco (http://www.cgl.
ucsf.edu/chimera/).57 ClustalW58 was used (with default
settings) to align the sequences of DNAJA1-JD with the J-
domains of four homologous proteins: E. coli DnaJ J-domain
[Protein Data Bank (PDB) entry 1XBL],59 Homo sapiens
Hsp40 (HDJ-1) J-domain (PDB entry 1HDJ),60 H. sapiens
HSJ1a (PDB entry 2LGW),61 and H. sapiens DnaJ subfamily C
member 12 (PDB entry 2CTQ). Electrostatic surface potentials
of the protein were calculated using Delphi.62 The identification
of evolutionarily conserved residues using both sequence and
structure was performed using the ConSurf server with default
settings.63
Identification of a Ligand Binding Site on the DNAJA1
J-Domain. To experimentally determine a potential functional
epitope or functionally relevant ligand binding site, we used a
high-throughput NMR ligand affinity screen using a function-
based compound library.64,65 The one-dimensional (1D) 1H
line broadening ligand-based screen and 2D 1H−15N HSQC
protein-based screen follow the same procedure outlined
elsewhere66,67 using 10 and 30 μM DNAJA1-JD (5% 13C-
labeled and 100% 15N-labeled), respectively. The concen-
trations for the compounds were 100 μM in the 1D 1H line
broadening screen and 400 μM in the 2D 1H−15N HSQC
screen.
The NMR spectra for the ligand affinity screens were
recorded on a 500 MHz Bruker Avance DRX spectrometer
equipped with a triple-resonance, Z-axis gradient cryoprobe
with a Bruker autotune and match (ATM) and BACS-120
sample changer. All 1D 1H NMR spectra were processed with
the ACD/NMR Processor (ACD/Laboratories), and 2D
1H−15N HSQC spectra were processed with NMRPipe43 and
visualized in CCPNMR Analysis.44
Chemical shift perturbations (CSPs) between the free and
ligand-bound 2D 1H−15N HSQC spectra of DNAJA1-JD were
used to define the consensus binding site. The CSPs were
calculated using a common weighting approach68 based on
changes in 15N and 1H chemical shifts that occur upon ligand
binding. AutoDock version 4.2.369−71 with the AutoDockTools
version 1.5.471,72 graphical interface was used to calculate 120
protein−ligand costructures, which were filtered using
AutoDockFilter73 to identify the costructures that best agree
with the experimental CSPs.
■ RESULTS AND DISCUSSION
Effect of DNAJA1 Overexpression on Cellular Stress
Modulation in Pancreatic Cancer Cells. DNAJA1 is related
to the cellular response to stress, a common event in the tumor
cells due to fluctuations in the nutrient and oxygen levels in the
tumor microenvironment or due to therapy, and can govern the
response of the tumor to chemo- and radiotherapies. Hence, we
performed cell-based functional assays of c-Jun phosphorylation
to identify DNAJA1-mediated activation of the stress response
pathway in cancer cells. c-Jun is a member of the JNK signaling
pathway, and its transcriptional activity and expression are
primarily regulated by the phosphorylation of two serines,
Ser63 and Ser73.74−77 c-Jun regulates a range of cellular
processes, including apoptosis, tumorigenesis, and cell pro-
liferation, which includes protecting cells from stress-induced
cell death.75,77 This makes c-Jun both a positive and negative
Figure 1. Protein sequence of DNAJA1 (UniProt entry P31689). The
red residues are the 67 amino acids of the J-domain (DNAJA1-JD).
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regulator of cell death. However, in several cancers, c-Jun has
been shown to inhibit apoptosis, leading to the uncontrolled
growth typical of cancer.78−80
Human MiaPaCa2 cells stably expressing full-length
DNAJA1 or the vector control were subjected to a 1 h
incubation with anisomycin (370 nM), a protein synthesis
inhibitor, or UV treatment at 20 or 50 J/m2 doses to mimic
stress. Activation of the stress-induced JNK pathway was
measured by evaluating the downstream phosphorylation of c-
Jun 20 min after treatment. The results indicate that the
overexpression of DNAJA1 (i.e., in cell line MiaPaCa2-
DNAJA1) diminishes the level of anisomycin and UV-induced
c-Jun phosphorylation at residue Ser63 (Figure 2A). Please
note the doubling of the c-Jun bands in Figure 2A is a result of
different phosphorylation states of c-Jun and, correspondingly,
different gel migration rates. Cell survival was also evaluated by
performing MTT assays 24 h after treatment with anisomycin.
The results indicate that DNAJA1 expression decreased the
level of cell survival under conditions of anisomycin treatment
(Figure 2B).
Expression of the DNAJA1 protein in MiaPaCa2 pancreatic
cancer cell lines results in the cells being more susceptible to
the stress-induced (UV-induced DNA damage or anisomycin-
induced inhibition of protein synthesis) diminution of the level
of cell survival (Figure 2). DNAJA1 expression also suppresses
the phosphorylation-mediated activation of the oncogenic
transcription factor, c-Jun, which is often overexpressed and
hyperphosphorylated in cancer81−83 and has an essential role in
pancreatic cancer.84,85
Interestingly, heat shock proteins have also been shown to be
regulators of apoptosis, where DnaK (Hsp70) suppresses JNK
activity.86−88 Thus, our preliminary results suggest DNAJA1
potentially stimulates the DnaK suppression of a JNK-induced
anti-apoptotic signaling pathway by forming a complex with
DnaK. This hypothesis is consistent with the 5-fold down-
regulation of DNAJA1 in pancreatic cancer cells, the resulting
suppression of c-Jun phosphorylation, and the corresponding
susceptibility to stress-induced apoptosis by expressing
DNAJA1. Obviously, protection from stress-induced apoptosis
by downregulating DNAJA1 would be beneficial because cancer
cells, by definition, exist in a stressful environment. To further
investigate this role of DNAJA1 in pancreatic cancer, we
determined an NMR solution structure.
Solution Structure of the DNAJA1 J-Domain. The
backbone resonance assignments were determined for 63
(98.4%) of the assignable 64 amino acid residues (excluding the
10 non-native residues to the N-terminal side of the His tag,
and the three Pro residues). The one amino acid for which the
amide could not be assigned, Met11, is the first residue
following the His tag. The side-chain assignments were
completed using a combination of CC(CO)NH, HCC(CO)-
NH, HCCH-COSY, and HCCH-TOCSY 3D NMR experi-
ments. The backbone and side-chain assignments, not including
the 10-residue His tag, were nearly complete with 63 of 67 N,
63 of 64 HN, 67 of 67 Cα, 70 of 70 Hα, 63 of 64 Cβ, 113 of
115 Cβ, 43 of 62 Cγ, 66 of 74 Hγ, 26 of 48 Cδ, 40 of 54 Hδ, 11
of 21 Cε, 14 of 34 Hε, 0 of 9 Cζ, and 0 of 1 Hζ atoms assigned.
Using the backbone resonance assignments, a model of
DNAJA1-JD was generated using CS-ROSETTA, which utilizes
chemical shifts to select protein fragments from the PDB
followed by Monte Carlo assembly and relaxation by
Rosetta.46,47 This tool has been shown to be effective in
predicting protein structures for small proteins (≤16 kDa). The
model generated from CS-ROSETTA exhibited the same
secondary structure as most DnaJ proteins and agreed with the
secondary structure predicted from TALOS+. All available
backbone and side-chain chemical shift assignments have been
deposited into the Biological Magnetic Resonance Data Bank
[BMRB (http://www.brmb.wisc.edu)] as entry 19163.
The solution structure of DNAJA1-JD was calculated using
1120 distance restraints, 116 dihedral restraints, 127 Cα/Cβ
chemical shift restraints, and 38 3JNHα coupling constant
restraints. The restraints used during the structure calculation
are summarized in Table 1. XPLOR-NIH was used to calculate
400 structures, and the 20 lowest-energy structures were
selected for further refinement in water using the RECOORD
protocol implemented in XPLOR-NIH. The resulting ensemble
and average structures (Figure 3A,B) agreed well with the
NMR data, where the experimental restraints had low root-
mean-square deviations (rmsds) (Table 1). The water-refined
average structure had no NOE violations greater than 0.5 Å or
dihedral violations greater than 5°. The water-refined ensemble
of 20 structures had a backbone rmsd of 0.709 ± 0.119 Å from
Figure 2. (A) Expression of full-length DNAJA1 (UniProt entry
P31689) in MiaPaCa2 pancreatic cancer cells suppresses the activation
of c-Jun in response to anisomycin (370 nM) or UV treatment (20 or
50 J/m2 doses). Twenty minutes after being treated, cells were
subjected to lysis, and the levels of phospho-c-Jun (S63) and total c-
Jun were evaluated by Western blotting. Expression levels of
exogenously expressed His-tagged DNAJA1 were evaluated by
immunoblotting with the anti-His antibody, while immunoblotting
with the anti-tubulin antibody was performed as a loading control. (B)
Expression of full-length DNAJA1 in MiaPaCa2 pancreatic cancer cells
decreases the level of survival in response to anisomycin treatment-
induced stress. The level of cell survival was measured by the MTT
assay 24 h after treatment (**p < 0.01; ***p < 0.001).
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Table 1. Structure Calculation Statisticsa
⟨SA⟩ (SA)r
rmsd for distance restraints (experimental) (Å)
all (1120) 0.083 ± 0.001 0.082
inter-residue sequential (|i − j| = 1) (269) 0.082 ± 0.003 0.086
inter-residue short-range (1 < |i − j| < 5) (221) 0.078 ± 0.005 0.073
inter-residue long-range (|i − j| ≥ 5) (80) 0.108 ± 0.008 0.098
intraresidue (500) 0.084 ± 0.002 0.085
H-bonds (50) 0.038 ± 0.008 0.029
rmsd for dihedral angle restraints (deg) (116) 0.027 ± 0.044 0.00
rmsd for Cα and Cβ shifts restraints (ppm) (127) 0.873 ± 0.036 0.907
rmsd for 3JNHα restraints (Hz) (38) 0.536 ± 0.038 0.540
rmsd (covalent geometry)
bonds (Å) 0.007 ± 0.000 0.007
angles (deg) 0.649 ± 0.015 0.647
impropers (deg) 0.794 ± 0.037 0.778
energy (kcal/mol)
total −2620.08 ± 70.18 −2834.43
bond 37.44 ± 2.35 36.16
angle 94.07 ± 4.69 95.65
dihedral 0.02 ± 0.04 0.00
impropers 33.44 ± 2.77 31.56
van der Waals −262.40 ± 10.76 −273.46
NOE 230.11 ± 7.09 226.01
3JNHα 10.99 ± 1.60 11.08
Cα and Cβ shifts 49.16 ± 4.30 52.92
a⟨SA⟩ represents the final 20 water-refined simulated annealing structures. (SA)r represents the water-refined average structure of all 20 water-refined
structures.
Figure 3. (A) Overlay of the backbone trace of the 20 lowest-energy, water-refined structures. (B) Ribbon representation of the average structure
generated from the average atomic coordinates of the 20 lowest-energy, water-refined structures, followed by water refinement of the average
structure. Both structures are colored according to secondary structure: red for α-helix and white for loop.
Table 2. Atomic Root-Mean-Square Differencesa
full protein (residues 11−77) secondary structure
backbone atoms all heavy atoms backbone atoms all heavy atoms
⟨SA⟩ vs SA 0.709 ± 0.119 1.417 ± 0.110 0.399 ± 0.086 1.232 ± 0.134
⟨SA⟩ vs (SA)r 0.888 ± 0.136 1.739 ± 0.139 0.639 ± 0.155 1.605 ± 0.131
(SA)r vs SA 0.649 1.217 0.523 1.183
a⟨SA⟩ represents the final 20 water-refined simulated annealing structures. SA represents the average structure of all 20 water-refined structures.
(SA)r represents the water-refined average structure of all 20 water-refined structures.
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the unrefined average coordinates. This result improves to
0.399 ± 0.086 Å when only the residues involved in the more
stable secondary structure elements are evaluated, which
indicates the consistency of the structure calculation using the
experimental restraints (Table 2). Comparing the original CS-
ROSETTA homology model to the final water-refined average
structure showed backbone rmsds of 1.803 Å (full protein) and
0.889 Å (secondary structure).
The RPF webserver and PSVS software suite were used to
verify the quality of the ensemble and average structures (Table
3). Few unreasonable atom clashes were identified by the
Molprobity module, and our DNAJA1-JD NMR structure has a
very good Z-score (−1.59) compared to the average Z-score for
NMR structures in the PDB (−10.74).52 This is actually
comparable to the Z-scores of medium-resolution X-ray crystal
structures in the PDB (−1.39).52 An evaluation of the probable
dihedral angles expected for each residue using PROCHECK
also shows excellent Z-scores (1.65 for ϕ and ψ dihedrals and
1.48 for all dihedrals). Additionally, 98.5% of the residues have
backbone dihedral angles in the most favored regions of
Ramachandran space; only one residue, Val12, has backbone ϕ
and ψ values in the more generously allowed region. The
discriminating power (DP-score), Recall, Precision, and F-
measure scores provide global measures of the goodness of fit
between the DNAJA1-JD NMR structure and the NOESY peak
list, where a DP-score of >0.75 and an F-measure of >0.8 are
consistent with high-quality structures. The DP-score and F-
measure calculated for the DNAJA1-JD NMR structure are
0.852 and 0.733, respectively. Overall, the results indicate that
the final ensemble and average models for DNAJA1-JD are
good-quality structures with few to no unreasonable structural
features. The coordinates of the water-refined ensemble have
been deposited in the PDB as entry 2M6Y.
The secondary structure and fold for DNAJA1-JD are similar
to those of other J-domains found in DnaJ homologues. In
effect, our DNAJA1-JD structure adopts the characteristic J-
domain found in most species. The structure consists of four α-
helices: residues 17−21 (α1), 29−42 (α2), 52−65 (α3), and
68−75 (α4) (Figure 3B). The loop between helices α2 and α3
(residues 43−51) contains the highly conserved His-Pro-Asp
(HPD) motif (residues 44−46).
The structures of 28 DnaJ proteins in various organisms have
been determined. Most of these proteins (16 structures) are
from humans, with the majority belonging to DnaJ subfamily B
(six) and DnaJ subfamily C (eight). The tertiary structure of
DNAJA1-JD was compared to a few representative structures:
E. coli DnaJ J-domain (PDB entry 1XBL), human DnaJ
homologue subfamily B member 1 J-domain (PDB entry
1HDJ), human DnaJ homologue subfamily B member 2 J-
domain (PDB entry 2LGW), and human DnaJ homologue
subfamily C member 12 J-domain (PDB entry 2CTQ). All four
proteins have essentially the same tertiary structure as
DNAJA1-JD with PDBeFold Z-scores of 5.148 (2.08 Å
rmsd), 6.872 (1.65 Å rmsd), 4.541 (2.24 Å rmsd), and 6.904
(1.37 Å rmsd), respectively (Figure 4A−D). The different DnaJ
homologue subfamilies do not appear to exhibit a significant
difference in structure, especially because the best matched
structure to DNAJA1 belongs to DnaJ homologue subfamily C.
Thus, the structural and functional difference between these
subfamilies likely occurs in the other DnaJ domains.
The human DNAJA1-JD sequence is also very well
conserved in J-domains from other organisms, with 56 proteins
having ≥49% identical sequences. The sequences of repre-
sentative DnaJ proteins 1XBL, 1HDJ, 2LGW, and 2CTQ have
51, 56, 47, and 32% identical sequences, respectively (Figure
4E). As expected, all five proteins have the highly conserved
HPD motif. Additionally, helix α2 is highly conserved except
for protein 2CTQ. This is interesting and potentially
functionally relevant because helix α2 tends to be positively
charged and represents a possible binding site for DnaK
(Hsp70).
Identification of Potential Protein Binding Sites on
the DNAJA1 J-Domain. One of the primary functions for
DnaJ is to stimulate the ATPase activity of DnaK. The primary
function of the J-domain of DnaJ is to bind to the ATPase
domain on DnaK. As previously mentioned, the main feature of
J-domain proteins is a highly conserved HPD motif, which may
indicate its importance in binding to DnaK. Thus, identifying a
ligand binding site that overlaps with this proposed DnaK
binding site would provide further validation of the location
and existence of a potential DnaK binding site. Critically, a
specific DnaK or DnaK-like protein that binds DNAJA1 has not
been identified. It is simply hypothesized to exist on the basis of
analogy with other DnaJ proteins.11
The PDB contains only one example of a J-domain in
complex with DnaK. This example (PDB entry 2QWN) is a
crystal structure of the bovine auxilin (DnaJ homologue
subfamily C) J-domain chemically cross-linked with bovine
DnaK at the conserved HPD motif.9,89 A sequence alignment of
the residues between the bovine auxilin J-domain and DNAJA1-
JD allows for a prediction of the proposed DnaJ−DnaK
interaction site (Figure 5A). This proposed binding site
includes the highly conserved HPD motif. However, there is
some contention about whether the cross-linked complex is
biologically relevant or whether auxilin accurately represents
most interactions of DnaJ with DnaK.89−91
A previous NMR analysis revealed chemical shift perturba-
tions (CSPs) in 2D 1H−15N HSQC experiments when the E.
coli DnaJ J-domain is bound to E. coli DnaK.92 The majority of




ProsaII (−ve) 2.40 2.52
Procheck (ϕ and ψ) 1.65 1.46
Procheck (all) 1.48 1.54
MolProbity clash score −1.59 −1.56
RPF scoresc
Recall 0.968 ± 0.001 0.965
Precision 0.762 ± 0.006 0.737
F-measure 0.852 ± 0.004 0.836
DP-score 0.733 ± 0.020 0.656
Ramachandran spaced (%)
most favored regions 98.5 98.5
allowed regions 1.5 1.5
disallowed regions 0.0 0.0
a⟨SA⟩ represents the final 20 water-refined simulated annealing
structures. (SA)r represents the water-refined average structure of all
20 water-refined structures. bCalculated with PSVS (http://psvs-1_5-
dev.nesg.org/). More positive scores are better. cCalculated with RPF
(http://nmr.cabm.rutgers.edu/rpf/). A DP-score of >0.75 and an F-
measure of >0.8 are consistent with high-quality structures.
dCalculated with the Molprobity module in PSVS.
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the perturbed residues in the E. coli DnaJ J-domain occurred
along helix α2. An alignment of the E. coli DnaJ J-domain and
human DNAJA1-JD sequences allowed us to map those same
perturbed residues onto the human DNAJA1-JD sequence and
structure (Figure 5B). This process identifies a possible DnaK
binding site on DNAJA1-JD that includes helix α2 instead of
Figure 4. Overlay of the ribbon structure for DNAJA1-JD (red) with (A) the E. coli DnaJ J-domain (PDB entry 1XBL), (B) the H. sapiens DnaJ
homologue subfamily B member 1 J-domain (PDB entry 1HDJ), (C) H. sapiens DnaJ homologue subfamily B member 2 (PDB entry 2LGW), and
(D) H. sapiens DnaJ homologue subfamily C member 12 (PDB entry 2CTQ). (E) ClustalW comparison of DNAJA1-JD (HR3099K) with PDB
entries 1HDJ (blue), 1XBL (green), 2LGW (yellow), and 2CTQ (cyan). The highly conserved HPD sequence is outlined with a black box. The
residues that make up helix α2 are outlined with a red box.
Figure 5. (A) Transparent surface and ribbon representation of DNAJA1-JD highlighting another proposed DnaK binding site based upon the
bovine auxilin−bovine Hsp70 complex (PDB entry 2QWN) (colored red and green; conserved HPD motif). (B) Transparent surface and ribbon
representation of DNAJA1-JD (rotated ∼90°) with the proposed DnaK binding site based upon NMR titration data (colored blue). (C) Transparent
surface and ribbon of DNAJA1-JD (rotated ∼90°) with the proposed inhibition site based upon the TIM14−TIM16 complex (colored purple). (D)
Sequence of DNAJA1-JD with the proposed interaction sites indicated: DnaK binding site from titrations (blue circle), DnaK inhibition site (purple
triangles), DnaK binding site from the cross-linked auxilin−Hsp70 complex (red stars), and the highly conserved HPD motif (green box). The
conserved HPD motif and helix α2, which is potentially an important component of the DnaJ−DnaK interaction site and the TIM16-like inhibitory
binding site, are labeled.
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the HPD motif predicted from the DnaJ−DnaK X-ray
structure. Helix α2 is an intriguing location for a potential
protein binding site because it presents a positively charged
surface. Coincidentally, the proposed DnaJ binding site on
DnaK has a negatively charged surface, which further supports
the identification of helix α2 as a binding site for DnaK.
Additionally, mutations of residues in helix α2 inhibit the
DnaJ−DnaK interaction, further implicating the importance of
helix α2 in binding DnaK.90,92
Another potential protein interaction site on DNAJA1-JD
may be linked to the inhibition of DnaJ activity. TIM14 is a
related DnaJ protein that is essential for the transport of
proteins across the outer membrane of mitochondria by
stimulating ATPase activity of mitochondrial Hsp70.93 Any
mutation in the HPD motif of TIM14 effectively inhibits its
activity, which indicates the importance of the HPD motif in
the function of DnaJ proteins. Importantly, TIM14 activity is
inhibited when TIM14 is bound to TIM16. TIM16 is another J-
domain-like protein, but it lacks the HPD motif. The location
of the TIM14−TIM16 interaction site partially overlaps with
the proposed DnaK binding site that includes residues in helix
α2.94 A sequence alignment of TIM14 with DNAJA1-JD
indicates an essentially identical overlap (Figure 5C), where
four of the 15 residues that make up the proposed DnaK
binding site are also part of the potential inhibition site (Figure
5D). Thus, the binding of a TIM16-like protein to DNAJA1
would sterically interfere with DnaK binding because of this
partial overlap in protein binding sites. Again, a TIM16-like
Figure 6. (A) Overlay of 2D 1H−15N HSQC spectra of free DNAJA1-JD (black) and DNAJA1-JD with O-phospho-L-serine (red). (B) Transparent
surface representation and ribbon diagram of DNAJA1-JD bound with O-phospho-L-serine, with the residues showing a chemical shift perturbation
upon binding of O-phospho-L-serine colored blue and the one residue, Glu51, that shows the greatest chemical shift perturbation with every binding
ligand colored red. (C) Expanded view of O-phospho-L-serine bound to a ribbon diagram of DNAJA1-JD, where residues with side chains directed
toward the ligand are displayed.
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protein that binds DNAJA1 has not been identified. Thus, the
DnaK binding site is located in the highly conserved HPD
motif or helix α2, where a potential inhibitory binding site also
involves helix α2. Our ligand binding assay may provide some
further insight regarding these potential protein binding sites
on DNAJA1-JD.
Identification of a Ligand Binding Site on the DNAJA1
J-Domain. A high-throughput NMR ligand affinity screen66,67
was performed with a function-based compound library.64,65
The library contains ∼460 biologically active compounds
consisting of known drugs, protein inhibitors, metabolites,
substrates, carbohydrates, fatty acids, hormones, and cofactors.
The 1D 1H line broadening screen identified 27 possible
binders. A 2D 1H−15N HSQC screen identified only seven
compounds that induced chemical shift perturbations (CSPs)
upon binding with DNAJA1-JD: O-phospho-L-serine, pyridoxal
5′-phosphate, Bay 11-7082, β-NADPH, ureidosuccinic acid, 2-
aminophenol, and D-glucosamine. The seven compounds
induced CSPs to the same set of residues, inferring a consistent
and unique ligand binding site. Most of the compounds are
small, and five of the compounds have a phosphate group or a
carboxylic acid group, both of which are likely to be
deprotonated at pH 7.0, leaving negatively charged molecules.
Importantly, the chemical library contained other compounds
with a phosphate or carboxylic acid groups that did not bind
DNAJA1-JD, eliminating the likelihood of a nonspecific binding
interaction driven only by charge interactions. No other
common chemical motif or scaffold is apparent.
Of the seven compounds, O-phospho-L-serine had the
greatest number of CSPs (nine) in the 2D 1H−15N HSQC
screen (Figure 6A). Using the size of O-phospho-L-serine and
our CSP-Consensus program, every residue with an observed
CSP was determined to be part of a consensus ligand binding
site. A DNAJA1-JD−O-phospho-L-serine costructure was then
determined on the basis of these CSPs using AutoDock and
AutoDockFilter, which identifies the docked pose that best
matches the chemical shift perturbation data.73 The costructure
selected by AutoDockFilter (Figure 6B) had an AutoDock
binding energy of −2.66 kcal/mol, which fits with the average
AutoDock binding energy of −2.54 ± 0.40 kcal/mol for all of
the docked poses. The costructure has nine residues with any
atom within 6 Å of the docked ligand: Ala40, Leu41, Lys42,
Tyr43, His44, Lys47, Asn48, Glu51, and Lys54 (Figure 6C). Six
of these residues were perturbed in the 2D 1H−15N HSQC
spectrum (Figure 6A). However, there may be some differences
between the predicted costructure and the actual complex in
solution because of local structural rearrangements upon ligand
binding. This is likely to occur because AutoDock used a static
model of DNAJA1-JD.
On the basis of the protein−ligand costructure, the binding
site coincides with the predicted inhibition site based on the
TIM14−TIM16 complex (Figure 7A). The O-phospho-L-serine
binding site is also consistent with the locations of chemical
shift perturbations observed for the other compounds shown to
bind in the FAST-NMR assay.66,67 Surprisingly, this ligand
binding site is not particularly well conserved (Figure 7B). This
fact would benefit a drug discovery effort that targets the
proposed DNAJA1−TIM16-like complex. While the J-domain
is a common fold, the predicted DNAJA1−TIM16-like
interaction site appears to be sequence specific, which means
drug selectivity can be achieved. Because most of the binding
ligands have negatively charged groups, it seems likely that the
compounds have an electrostatic interaction with the positively
charged region on helix α2 (Figure 7C). Additionally, most of
the protein surface, including the binding site, consists of
hydrophilic residues, indicating that hydrophobic interactions
are unlikely to be energetically favorable. These properties may
explain why most of the ligands shown to bind to DNAJA1-JD
were small and negatively charged. Nevertheless, these results
provide further support for the existence of an inhibitory
protein binding site on DNAJA1-JD and the importance of
helix α2 to the function of DNAJA1-JD. It is important to note
that the ligands shown to bind DNAJA1-JD have a low binding
affinity (KD > 100 to 50 μM), are unlikely to inhibit protein−
protein interactions, and have not been shown to inhibit
DNAJA1-JD protein binding or to be biologically active in
pancreatic cancer cells. Instead, they are simple chemical probes
of DNAJA1-JD functional epitopes and provide experimental
evidence that supports the identification of the predicted
inhibitory protein binding site on DNAJA1-JD.
■ CONCLUSIONS
Cell-based functional assays showed that the overexpression of
DNAJA1 suppresses the stress response capabilities of the
oncogenic transcription factor, c-Jun, which is often overex-
pressed and hyperphosphorylated in cancer cells. c-Jun is part
of the JNK signaling pathway, and its phosphorylation state can
promote apoptosis or cell proliferation. DnaK has previously
been shown to suppress the JNK pathway, which inhibits the
hyperphosphorylated, anti-apoptosis state found in pancreatic
Figure 7. Transparent surface representation and ribbon diagram of DNAJA1-JD bound with O-phospho-L-serine with (A) the proposed inhibition
site based on the TIM14−TIM16 interaction (purple), (B) the highly conserved (magenta) and poorly conserved (cyan) residues from Consurf, and
(C) the positively charged surface (blue) and negatively charged surface (red) from Delphi. Helix α2, which is potentially an important component
of the DnaJ−DnaK interaction site and the TIM16-like inhibitory binding site, is labeled.
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cancer cells. The DNAJA1-JD NMR structure combined with a
bioinformatics analysis and a ligand affinity screen identified a
potential DnaK-like binding site and TIM16-like inhibitory
binding site. Interestingly, both of these binding sites involve
conserved helix α2 and suggest DNAJA1 activity is highly
regulated. The NMR ligand affinity screen provided further
experimental support for the existence of the TIM16-like
inhibitory binding site. On the basis of these observations, we
propose a stress response pathway involving DNAJA1 (Figure
8). In the absence of stress, DNAJA1 would be inactivated by
forming an inhibitory complex with a TIM16-like protein. In
the presence of environmental stress, DNAJA1 would activate a
DnaK protein by forming a complex that suppresses the JNK
pathway, the hyperphosphorylation of c-Jun, and the anti-
apoptosis state. Conversely, the downregulation of DNAJA1 in
pancreatic cancer cells likely lowers the activity of DnaK even
under conditions of stress, which allows for the hyper-
phosphorylation of c-Jun and the cell proliferation that is a
hallmark of cancer. Thus, the overlapping protein binding
interfaces on DNAJA1-JD may be interesting targets for future
drug discovery efforts related to pancreatic cancer. Specifically,
a drug that disrupts the predicted DNAJA1−TIM16-like
inhibitory complex may activate DnaK even in the absence of
a stress response. Thus, a constitutively active DnaK may lead
to a cascade of events resulting in cell death through the
inactivation of JNK and a decrease in the level of c-Jun
phosphorylation. Because the overexpression of DNAJA1
reduces pancreatic cancer cell survivability under stress, the J-
domain of DNAJA1 itself may be a valuable biological target for
treating pancreatic cancer as part of a combination therapy.
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